Georgetown Lombardi Comprehensive Cancer Center | Strategic Alliance Partners

April 29, 2024

Stacey Cohen, MD, discusses the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA study evaluating adjuvant chemotherapy selection based on MRD, and the panel discusses barriers to enrollment.

April 29, 2024

The panel continues its review of data presented on MRD testing in colorectal cancer from the INTERCEPT and COSMOS-CRC-01 studies.

April 23, 2024

The panel reviews recent data on MRD testing in colorectal cancer, highlighting the INTERCEPT and COSMOS-CRC-01 studies.

April 23, 2024

Benjamin A. Weinberg, MD, presents the case of a 35-year-old man with oligometastatic disease, and the panel provides insights on treatment decisions.

April 15, 2024

Pashtoon Murtaza Kasi, MD, MS, emphasizes key aspects of liquid biopsy and ctDNA testing in the MRD treatment landscape.

April 15, 2024

Pashtoon Murtaza Kasi, MD, MS, reviews data from the BESPOKE CRC study, highlighting overall results and patient-reported outcomes.

April 09, 2024

Focusing on the GALAXY arm in the CIRCULATE-Japan study, experts on colorectal cancer discuss how recent data are informing the evolving treatment landscape.

April 01, 2024

John L. Marshall, MD, presents the case of a 52-year-old woman with mid-rectal carcinoma, and the panel offers its initial impressions.

April 01, 2024

The panel discusses how MRD testing has evolved as a clinical tool in colorectal cancer, highlighting the phase 2/3 COBRA study and its implications.

March 25, 2024

Experts on colorectal cancer discuss practical considerations related to MRD testing, highlighting strategies to navigate potential challenges.

March 25, 2024

Pashtoon Murtaza Kasi, MD, MS, discusses MRD testing practices in the community oncology setting and provides recommendations on the integration of MRD testing into clinical practice.

March 18, 2024

Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.

March 18, 2024

Colorectal cancer specialists discuss MRD testing platforms and how to choose among the available testing assays.

March 11, 2024

Experts on colorectal cancer discuss the timing of testing for minimal residual disease in the treatment journey.

March 11, 2024

A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.

February 23, 2024

Chul Kim, MD, MPH, discusses the impact of optimizing rare targets in lung cancer, highlighting the FDA approval of repotrectinib in ROS1-positive disease.

November 17, 2023

John Lindsay Marshall, MD, sheds light on the significance of the FDA approval of fruquintinib for patients with heavily pretreated metastatic colorectal cancer and discusses the efficacy and safety data from the FRESCO and FRESCO-2 trials that supported the decision in this population.

November 09, 2023

John Lindsay Marshall, MD, discusses the significance of the FDA approval of fruquintinib (Fruzaqla) in patients with metastatic colorectal cancer.

October 31, 2023

Stephen V. Liu, MD, discusses the significance of using fam-trastuzumab deruxtecan-nxki in patients with HER2-mutant non–small cell lung cancer and brain metastases according to pooled findings from exploratory analyses of the phase 2 DESTINY-Lung01 and DESTINY-Lung02 trials.

October 30, 2023

Stephen V. Liu, MD, discusses the interim analysis of the phase 2 TRUST-II trial, which is investigating the use of taletrectinib in patients with ROS1-positive non–small cell lung cancer.